Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Episode 26 with Dr. Tim Kennedy on remyelination and oligodendrocyte development
Interleukin-1beta promotes repair of the CNS.
Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Episode 19 with Dr. Samuel Ludwin on treating MS subtypes
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Extraocular Source of Oligodendrocytes Contribute to Retinal Myelination and Optokinetic Responses in Zebrafish.
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Firategrast
Autoantibodies and pain.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Optical Coherence Tomography: A Potential Noninvasive Follow-up Tool in Multiple Sclerosis.
Episode 16 with Dr. Revere [double-quote]Rip[double-quote] Kinkel on how to improve patient outreach
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis.
Dimethyl fumarate for multiple sclerosis.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.

Pages